Ascenta Therapeutics

About Ascenta Therapeutics

Ascenta Therapeutics, Inc. operated as a clinical-stage biopharmaceutical company focused on developing new medicines for cancer treatment. Founded in 2003, the company's core strategy revolved around discovering and developing small-molecule drugs that trigger apoptosis, the natural process of programmed cell death in cancer cells. The company was established by Dr. Shaomeng Wang, Dr. Marc E. Lippman, and Dr. Dajun Yang, who were all professors at the University of Michigan at the time. The technology was licensed from the University of Michigan, specifically from the laboratory of Dr. Wang, and the National Institutes of Health.

The founders brought a wealth of relevant experience to the venture. Dr. Shaomeng Wang is a chemist with a Ph.D. from Case Western Reserve University and extensive research focused on designing small-molecule therapeutics and targeting protein-protein interactions that regulate apoptosis. Dr. Marc E. Lippman is a renowned medical oncologist with a medical degree from Yale, specializing in breast cancer research. Dr. Dajun Yang holds a Ph.D. in Genetics from Michigan State University and has a background in oncology research and preclinical development. This collective expertise in chemistry, clinical oncology, and drug development formed the scientific foundation of Ascenta.

Ascenta's business model was centered on capital-efficient drug development, which included conducting discovery work in alliance with universities and preclinical research at its facility in Shanghai, China, while clinical development was managed from its US offices in Malvern, Pennsylvania, and San Diego, California. The company's revenue model relied on strategic collaborations and licensing agreements with large pharmaceutical companies. A significant milestone was a 2010 global licensing agreement with sanofi-aventis for its program targeting the HDM2-p53 protein-protein interaction, a deal potentially worth up to $398 million in milestone payments and royalties. Another key collaboration was formed with Ascentage Pharma Group to co-develop two of its clinical-stage assets, AT-101 and AT-406, leveraging manufacturing and development capabilities in both the US and China.

The company's product pipeline included several orally active, small-molecule drug candidates. Its lead agent, AT-101, was a pan-Bcl-2 inhibitor designed to block multiple anti-apoptotic proteins. AT-406 was a multi-IAP (inhibitor of apoptosis proteins) antagonist intended to mimic the activity of the natural Smac protein to induce cancer cell death. A third program focused on developing HDM2 inhibitors to restore the tumor suppressor function of the p53 protein. These programs progressed through various stages of clinical trials, with AT-101 reaching Phase 2 and AT-406 entering Phase 1. Public records indicate the company is now out of business.